Announced Sat, 14 Mar · 14:32 IST

DISCLOSURE RECEIVED UNDER REGULATION 7(2) OF SECURITIES EXCHANGE BOARD OF INDIA(PROHIBITION OF INSIDER TRADING) REGULATIONS, 2015

Promoter Stake BuyOwnership Changes View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-4.7%1-day move

₹20.20

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————-4.7-1.0+3.9+5.9+1.5+0.5+28.7+21.4-0.5+16.3

Up moveDown movePending

AI summary

Sudhir Sethi, the main Promoter and Director of Beryl Drugs Ltd, has purchased 3,040 shares of the company on the open market, increasing his holding from 470,163 to 473,203 shares. This acquisition represents a tiny 0.06% stake in the company. The disclosure has been filed with BSE under SEBI's Prohibition of Insider Trading Regulations, as required for any share dealings by promoters or directors. The transaction was carried out on 14 March 2026.

Likely market impact

The size of this purchase is very small (just 3,040 shares), so it is unlikely to move the stock price or signal a major confidence shift. It appears to be a routine insider trade disclosure rather than a meaningful accumulation.